Abstract Library

#4667 Clinical outcomes in patients with typical (TC) and atypical bronchial carcinoids (AC): A 15-year retrospective study from an ENETS Center of Excellence

Introduction: Bronchial neuroendocrine neoplasms (NENs) can be subdivided into TCs, ACs and neuroendocrine carcinomas (NECs). Although a few studies have explored treatment approaches and oncological outcomes, most focus on surgical cohorts, small sample sizes, or mixed groups including TC, AC, and NECs. Real-life cohort data are lacking.

Conference:

Presenting Author: Clement D

Authors: Correia J, Sarker D, Dolly S, Frydman A, Srirajaskanthan R,

Keywords: bronchial carcinoid, treatment pattern, recurrence-free survival, overall survival,

#3620 Real-world SEER-Medicare data analysis of the evolution of tumor characteristics, first-line therapies and overall survival (OS) in patients with neuroendocrine tumors (NETs)

Introduction: Recent data on NET therapy utilization and impact in real-world practice are scarce.

Conference:

Presenting Author:

Authors: Schneider M, Sinha A, Dasari A, Chan J, Stoffels A,

Keywords: neuroendocrine tumor, NET characteristics, first-line therapy, treatment evolution, treatment patterns, overall survival,

#3453 Comparison of Lanreotide and Octreotide LAR use and outcomes for gastrointestinal neuroendocrine tumors in British Columbia, Canada

Introduction: The long-acting somatostatin analogues (LA-SSAs) octreotide LAR (OCT) and lanreotide (LAN) improve progression-free survival in neuroendocrine tumors (NETs), however no head-to-head comparison exists. We compared treatment patterns and efficacy in a population-based cohort from British Columbia, Canada.

Conference:

Presenting Author: Paul A

Authors: Paul A, Mendis S, Jao J, Boutin M, Safro M,

Keywords: lanreotide, octreotide LAR, neuroendocrine tumor, overall survival,

#3067 Somatostatin Analogs in Real‐World Practice for Patients with Metastatic Neuroendocrine Tumors: A Single Institution Experience in the Ouest of Algeria (CHU Oran)

Introduction: The efficacy of somatostatin analogs (SSAs) were clearly established trough pivotal trials as first‐line agents for neuroendocrine tumors (NETs), but their use in clinical practice is largely unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ameziane N, Behourah Z, Aida M, Ahed Messaoud M, Bousahba A,

Keywords: GEP-NET, Somatostatin analogs, anti proliferative action, anti secretory action, Management real world practice,

#2969 Lanreotide Autogel and Octreotide LAR Treatment Patterns: Results from a Nationwide French Retrospective Study

Introduction: Lanreotide autogel (LAN) and octreotide LAR (OCT) are long acting somatostatin analogues (LA-SSAs) used to treat acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Previous studies conducted in North America and Sweden showed some differences between both LA-SSAs in terms of dose and persistence.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Fagnani F, Feuilly M, Marteau F, de Zélicourt M, Kamenicky P,

Keywords: somatostatin analogues, treatment patterns, resource use,